Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dinah Sah, Bernard Ravina, David Rodman, Casi DeYoung

Premium

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

Sah was previously vice president of research at Alnylam Pharmaceuticals.

Voyager has also appointed Bernard Ravina to the position of vice president of clinical development. He most recently was medical director of clinical development at Biogen Idec.


MiRagen Therapeutics has named David Rodman as executive vice president of research and development.

Rodman was most recently vice president of clinical development at Vertex Pharmaceuticals.


Mirna Therapeutics said it has named Casi DeYoung as its chief business officer.

Previously, DeYoung was vice president of business development at ODC Therapy.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.